Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sheel BiotechNSE:SHEEL 18 Net Current Asset Value is ₹53.57 as of Mar. 2026, which is 100% below its 10-year median of 0.75. GuruFocus rates NSE:SHEEL with a GF Score™ of 18/100. The stock has 2 warning signs investors should review. Among 1,052 Consumer Packaged Goods companies, Sheel Biotech ranks better than 86.31% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Sheel Biotech's net current asset value per share for the quarter that ended in Mar. 2026 was ₹53.57.
The historical rank and industry rank for Sheel Biotech's Net Current Asset Value or its related term are showing as below:
NSE:SHEEL'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.75 Med: 0.75 Max: 1.31
Current: 1.27
During the past 5 years, the highest Price-to-Net-Current-Asset-Value Ratio of Sheel Biotech was 1.31. The lowest was 0.75. And the median was 0.75.
NSE:SHEEL's Price-to-Net-Current-Asset-Value is ranked better than 86.31% of 1052
companies
in the Consumer Packaged Goods industry
Industry Median: 4.155
vs NSE:SHEEL: 1.27
Sheel Biotech (NSE:SHEEL) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Sheel Biotech Net Current Asset Value Related Terms
Sheel Biotech Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Sheel Biotech's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sheel Biotech Net Current Asset Value Chart
Sheel Biotech Annual Data
Trend
Mar22
Mar23
Mar24
Mar25
Mar26
Net Current Asset Value
24.50
25.77
30.53
35.21
53.57
Sheel Biotech Semi-Annual Data
Mar22
Mar23
Mar24
Mar25
Mar26
Net Current Asset Value
24.50
25.77
30.53
35.21
53.57
NSE:SHEEL vs ADM, BG, TSN: Net Current Asset Value Comparison
For the Farm Products subindustry, Sheel Biotech's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sheel Biotech Price-to-Net-Current-Asset-Value vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Sheel Biotech's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Sheel Biotech's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of ₹53.57 mean?
Sheel Biotech (NSE:SHEEL) has a Net Current Asset Value of ₹53.57 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Sheel Biotech and its competitors. This is 7043% above median its historical median of 0.75. Over the past decade, Sheel Biotech's Net Current Asset Value has ranged from 0.75 to 1.31. According to the industry distribution chart, Sheel Biotech ranks #144 out of 1052 companies in the Consumer Packaged Goods industry, placing it in the top 13.7%.
Is Sheel Biotech's Net Current Asset Value too high?
Sheel Biotech's current Net Current Asset Value of ₹53.57 is 7043% above median its 10-year median of 0.75. Over the past 10 years, this metric has ranged from a low of 0.75 to a high of 1.31. Based on the distribution chart, Sheel Biotech ranks #144 out of 1052 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Sheel Biotech has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Sheel Biotech's Net Current Asset Value compare to ADM and BG?
According to the Consumer Packaged Goods industry distribution chart, Sheel Biotech ranks #144 out of 1052 companies for Net Current Asset Value. This places Sheel Biotech in the top 14% of its industry — outperforming the majority of peers. The industry median Net Current Asset Value is 4.16. Historically, Sheel Biotech's own Net Current Asset Value has ranged from 0.75 to 1.31 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Consumer Packaged Goods company?
The median Net Current Asset Value among Consumer Packaged Goods companies is 4.16, based on 1,052 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Sheel Biotech and its competitors. For the Consumer Packaged Goods industry, the median Net Current Asset Value is 4.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sheel Biotech's current Net Current Asset Value is ₹53.57, which is 7043% above median its own 10-year median of 0.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sheel Biotech stock overvalued right now?
Sheel Biotech (NSE:SHEEL) has a current Net Current Asset Value of ₹53.57. The current Net Current Asset Value is ₹53.57, which is 7043% above median its 10-year median of 0.75. Sheel Biotech's overall GF Score™ is 18/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Sheel Biotech (NSE:SHEEL), the current Net Current Asset Value is ₹53.57 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sheel Biotech Ltd is engaged in the business of growing, developing, processing, and supplying a wide range of plants for field crops, fruits, vegetables, and ornamental plants through tissue culture and organic farming. It manufactures and maintain greenhouses, offer services to farmers and provide training through Farmer Producer Organizations (FPOs). The company also has a Research and Development lab with a capacity of production of 10 million* planting materials which is duly recognized by the Department of Biotechnology (DBT), Government of India.
18GF Score
Get the complete analysis for NSE:SHEEL
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SHEEL has been successfully added to your 
